‌

US Patent 10738117 Antibodies directed against programmed death-1 (PD-1)

Patent 10738117 was granted and assigned to AnaptysBio on August, 2020 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors

Is a

Patent

Patent attributes

Patent Applicant

AnaptysBio

Current Assignee

AnaptysBio

Patent Jurisdiction

United States Patent and Trademark Office

Patent Number

107381170

Date of Patent

August 11, 2020

Patent Application Number

157262870

Date Filed

October 5, 2017

Patent Citations Received

‌

US Patent 11407830 Methods of treating cancer with anti-PD-1 antibodies

‌

US Patent 11622961 Combination therapies for treating cancer

‌

US Patent 11661453 Combination therapies for treating cancer with niraparib and PD-1 inhibitors

‌

US Patent 11801240 Combination therapies and uses thereof

Patent Primary Examiner

‌

Jessica H Roark

No article content yet.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 10738117 Antibodies directed against programmed death-1 (PD-1)

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Access by API